Literature DB >> 30393598

COX-2 inhibitors in NSCLC: never-ending story or misplaced?

Alex Martinez-Marti1, Alejandro Navarro1, Enriqueta Felip1.   

Abstract

Entities:  

Year:  2018        PMID： 30393598      PMCID： PMC6193903          DOI： 10.21037/tlcr.2018.04.17

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  23 in total

1.  Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.

Authors:  Andrea Koch; Bengt Bergman; Erik Holmberg; Christer Sederholm; Lars Ek; Jaroslaw Kosieradzki; Kristina Lamberg; Lars Thaning; Sven-Olof Ydreborg; Sverre Sörenson
Journal:  Eur J Cancer       Date:  2011-05-10       Impact factor: 9.162

2.  Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer.

Authors:  F R Khuri; H Wu; J J Lee; B L Kemp; R Lotan; S M Lippman; L Feng; W K Hong; X C Xu
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

3.  Downregulation of plasma membrane expression/cytoplasmic accumulation of beta-catenin predicts shortened survival in non-small cell lung cancer. A clinicopathologic study of 100 cases.

Authors:  L Kren; M Hermanová; V N Goncharuk; P Kaur; J S Ross; Z Pavlovský; K Dvorák
Journal:  Cesk Patol       Date:  2003-01

4.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.

Authors:  T Hida; Y Yatabe; H Achiwa; H Muramatsu; K Kozaki; S Nakamura; M Ogawa; T Mitsudomi; T Sugiura; T Takahashi
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

5.  The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.

Authors:  Cyril Sobolewski; Claudia Cerella; Mario Dicato; Lina Ghibelli; Marc Diederich
Journal:  Int J Cell Biol       Date:  2010-03-17

6.  Sulindac suppresses beta-catenin expression in human cancer cells.

Authors:  Anjia Han; Zibo Song; Chang Tong; Dong Hu; Xiuli Bi; Leonard H Augenlicht; Wancai Yang
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

Review 7.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

8.  Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.

Authors:  Cesare Gridelli; Ciro Gallo; Anna Ceribelli; Vittorio Gebbia; Teresa Gamucci; Fortunato Ciardiello; Francesco Carozza; Adolfo Favaretto; Bruno Daniele; Domenico Galetta; Santi Barbera; Francesco Rosetti; Antonio Rossi; Paolo Maione; Francesco Cognetti; Antonio Testa; Massimo Di Maio; Alessandro Morabito; Francesco Perrone
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer.

Authors:  Hassan Lemjabbar-Alaoui; Vijay Dasari; Sukhvinder S Sidhu; Aklilu Mengistab; Walter Finkbeiner; Marianne Gallup; Carol Basbaum
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240
View more
  2 in total

Review 1.  Insights into the Mechanisms of Action of Proanthocyanidins and Anthocyanins in the Treatment of Nicotine-Induced Non-Small Cell Lung Cancer.

Authors:  Naser A Alsharairi
Journal:  Int J Mol Sci       Date:  2022-07-18       Impact factor: 6.208

Review 2.  Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.

Authors:  Carlo Genova; Chiara Dellepiane; Paolo Carrega; Sara Sommariva; Guido Ferlazzo; Paolo Pronzato; Rosaria Gangemi; Gilberto Filaci; Simona Coco; Michela Croce
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.